Information  X 
Enter a valid email address

Omega Diagnostics Gp (ODX)

  Print   

Monday 15 February, 2021

Omega Diagnostics Gp

Director/PDMR Shareholding

RNS Number : 0212P
Omega Diagnostics Group PLC
15 February 2021
 

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Director/PDMR Shareholding

Exercise of Options

and Total Voting Rights

 

Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that it has allotted in total 1,691,013 new ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares"). This is following the exercise of share options under the Company's Third Unapproved Scheme by William Rhodes and Jeremy Millard, both Non-Executive Directors, and, under the Company's EMI Option Scheme by Jag Grewal, Commercial Director and Kieron Harbinson, Group Finance Director (together the "Exercising Directors").

 

In addition to the above dealings by the Exercising Directors, the Company has also received valid notices to exercise a further 74,347 share options from employees under the Company's Sharesave scheme. Of this amount, 5,869 Ordinary Shares were exercised and subsequently sold by Jamie Yexley, Operations Director and PDMR of the Company, at a price of 82.25 pence per Ordinary Share, following this transaction his holding in the Company remains unchanged.

 

Further to the exercise of share options by the Exercising Directors as detailed above, the Company announces that the Exercising Directors have subsequently sold in aggregate 1,616,666 new Ordinary Shares at an average price of 87.28 pence per Ordinary Share. Additionally, Kieron Harbinson has notified the Company that he has sold a further 175,000 Ordinary Shares in the Company at an average price of 89.76 pence per Ordinary Share. As a consequence, the equity interests of the Exercising Directors following the above transactions are as follows:

 

Director

Current Ordinary Share holding

Options exercised

Ordinary Shares sold

Resultant Ordinary Share holding

Resultant holding as a % of issued share capital post Admission

 Options held post exercise

William Rhodes

nil

300,000

300,000

nil

nil

1,830,406

Jeremy Millard

525,000

166,666

166,666

525,000

0.29%

333,334

Jag Grewal

235,746

210,000

210,000

235,746

0.13%

1,200,000

Kieron Harbinson

717,531

940,000

1,115,000

542,531

0.30%

750,000

 

Application will be made to the London Stock Exchange for the 1,691,013 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 19 February 2021.

 

Following Admission, the total number of Ordinary Shares in issue will be 181,758,167 and the total number of voting rights will therefore be 181,758,167. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.

 

Contacts: 

 

Omega Diagnostics Group PLC 

Tel: 01259 763 030

Colin King, Chief Executive 

www.omegadiagnostics.com

Kieron Harbinson, Group Finance Director




finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash / Teddy Whiley (Corporate Finance)


Alice Lane (ECM)




Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

William Rhodes

2

Reason for notification

 

a.

Position/Status

Non-Executive Director

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Omega Diagnostics Group Plc

b.

LEI

2138007U9P4BTZTYIR92

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

 Ordinary Shares of 4 pence each

 

ISIN:  GB00B1VCP282

b.

Nature of the transaction

Acquisition of Ordinary Shares following the Exercise of Share Options and Sale of Ordinary Shares

c.

Price(s) and volume(s)







Price(s)

Volume(s)


15.25 p

300,000

Purchase


87.2797p

300,000

Sale


d.

Aggregated information

Aggregated Purchase Volume

Aggregated Purchase Price

Aggregated Sale Volume

Aggregated Sale Price

As above. 

 

e.

Date of the transaction

12 February 2021

f.

Place of the transaction

London Stock Exchange

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Jeremy Millard

2

Reason for notification

 

a.

Position/Status

Non-Executive Director

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Omega Diagnostics Group Plc

b.

LEI

2138007U9P4BTZTYIR92

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

 Ordinary Shares of 4 pence each

 

ISIN:  GB00B1VCP282

b.

Nature of the transaction

Acquisition of Ordinary Shares following the Exercise of Share Options and Sale of Ordinary Shares

c.

Price(s) and volume(s)







Price(s)

Volume(s)


10 p

166,666

Purchase


87.2797p

166,666

Sale


d.

Aggregated information

Aggregated Purchase Volume

Aggregated Purchase Price

Aggregated Sale Volume

Aggregated Sale Price

As above. 

 

e.

Date of the transaction

12 February 2021

f.

Place of the transaction

London Stock Exchange

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Jag Grewal

2

Reason for notification

 

a.

Position/Status

Commercial Director

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Omega Diagnostics Group Plc

b.

LEI

2138007U9P4BTZTYIR92

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

 Ordinary Shares of 4 pence each

 

ISIN:  GB00B1VCP282

b.

Nature of the transaction

Acquisition of Ordinary Shares following the Exercise of Share Options and Sale of Ordinary Shares

c.

Price(s) and volume(s)







Price(s)

Volume(s)


13.25p

14.5p

 

100,000

110,000

 

Purchase


87.2797p

210,000

Sale


d.

Aggregated information

Aggregated Purchase Volume

Aggregated Purchase Price

Aggregated Sale Volume

Aggregated Sale Price

 

210,000

13.90p

 

210,000

87.2797p

e.

Date of the transaction

12 February 2021

f.

Place of the transaction

London Stock Exchange

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Kieron Harbinson

2

Reason for notification

 

a.

Position/Status

Chief Finance Director

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Omega Diagnostics Group Plc

b.

LEI

2138007U9P4BTZTYIR92

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

 Ordinary Shares of 4 pence each

 

ISIN: GB00B1VCP282

b.

Nature of the transaction

Acquisition of Ordinary Shares following the Exercise of Share Options and Sale of Ordinary Shares

c.

Price(s) and volume(s)







Price(s)

Volume(s)


14.5p

30.5p

 

300,000

640,000

 

Purchase


87.2797p

89.76p

940,000

175,000

Sale


d.

Aggregated information

Aggregated Purchase Volume

Aggregated Purchase Price

Aggregated Sale Volume

Aggregated Sale Price

 

940,000

25.39p

 

1,115,000

87.66p

 

e.

Date of the transaction

12 February 2021

f.

Place of the transaction

London Stock Exchange

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Jamie Yexley

2

Reason for notification

 

a.

Position/Status

Operations Director / PDMR

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Omega Diagnostics Group Plc

b.

LEI

2138007U9P4BTZTYIR92

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

 Ordinary Shares of 4 pence each

 

ISIN:  GB00B1VCP282

b.

Nature of the transaction

Acquisition of Ordinary Shares following the Exercise of Share Options and Sale of Ordinary Shares

c.

Price(s) and volume(s)







Price(s)

Volume(s)


18.4p

5,869

Purchase


82.25p

5,869

Sale


d.

Aggregated information

Aggregated Purchase Volume

Aggregated Purchase Price

Aggregated Sale Volume

Aggregated Sale Price

As above. 

 

e.

Date of the transaction

12 February 2021

f.

Place of the transaction

London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBBGDDUDBDGBS

a d v e r t i s e m e n t